FY2024 Earnings Estimate for GYRE Issued By Noble Financial

Gyre Therapeutics, Inc. (NASDAQ:GYRE) – Noble Financial issued their FY2024 earnings per share (EPS) estimates for Gyre Therapeutics in a note issued to investors on Tuesday, March 11th. Noble Financial analyst R. Leboyer forecasts that the company will post earnings per share of $0.17 for the year. Noble Financial has a “Outperform” rating on the stock. Noble Financial also issued estimates for Gyre Therapeutics’ Q4 2024 earnings at $0.04 EPS, Q1 2025 earnings at $0.03 EPS, Q2 2025 earnings at $0.03 EPS, Q3 2025 earnings at $0.15 EPS, Q4 2025 earnings at $0.21 EPS, FY2025 earnings at $0.42 EPS, FY2026 earnings at $1.17 EPS, FY2027 earnings at $1.72 EPS and FY2028 earnings at $2.90 EPS.

Gyre Therapeutics Price Performance

NASDAQ:GYRE opened at $11.67 on Thursday. The business’s 50-day simple moving average is $11.24 and its two-hundred day simple moving average is $12.32. Gyre Therapeutics has a 52 week low of $8.26 and a 52 week high of $19.96.

Insider Buying and Selling at Gyre Therapeutics

In other Gyre Therapeutics news, President Songjiang Ma sold 2,000 shares of the firm’s stock in a transaction dated Thursday, December 26th. The stock was sold at an average price of $12.70, for a total transaction of $25,400.00. Following the sale, the president now directly owns 2,928,467 shares of the company’s stock, valued at $37,191,530.90. This trade represents a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 34,054 shares of company stock valued at $383,057 over the last ninety days. 19.52% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Gyre Therapeutics

A number of hedge funds have recently made changes to their positions in GYRE. FMR LLC purchased a new stake in shares of Gyre Therapeutics in the third quarter worth about $47,000. Wells Fargo & Company MN lifted its position in shares of Gyre Therapeutics by 29.4% in the fourth quarter. Wells Fargo & Company MN now owns 4,016 shares of the company’s stock worth $49,000 after buying an additional 913 shares in the last quarter. Bank of America Corp DE lifted its position in shares of Gyre Therapeutics by 40.4% in the fourth quarter. Bank of America Corp DE now owns 6,937 shares of the company’s stock worth $84,000 after buying an additional 1,996 shares in the last quarter. Barclays PLC increased its stake in Gyre Therapeutics by 281.8% during the third quarter. Barclays PLC now owns 9,288 shares of the company’s stock worth $116,000 after acquiring an additional 6,855 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its stake in Gyre Therapeutics by 11.1% during the fourth quarter. Bank of New York Mellon Corp now owns 13,896 shares of the company’s stock worth $168,000 after acquiring an additional 1,389 shares during the last quarter. 23.99% of the stock is currently owned by hedge funds and other institutional investors.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.